P3 Long Term Healthcare Costs and Utilization Among Patients with Non Obstructive Hypertrophic Cardiomyopathy

Objectives There is limited evidence on the economic burden for patients with non-obstructive hypertrophic cardiomyopathy (nHCM). We analyzed cumulative healthcare resource utilization (HRU) and costs for patients with nHCM over a 5-year follow-up period. Methods Retrospective cohort study of adults (≥18 years) diagnosed with nHCM (January 2013- December 2021) in Optum’s claims and electronic medical record data. Patients had ≥2 claims (first= index date) with a diagnosis code for nHCM (ICD-9/10) at least 30 days apart, 6-months pre index and 5-years follow-up. Cardiovascular (CV)-related cumulative HRU and costs (CPI 2022) were reported as mean [SD], including medical (ambulatory: office visit, outpatient [OP] visits; emergency room [ER] visit; inpatient admissions (IA); length of stay [LOS]; other medical costs) and pharmacy. Results Among 3,652 nHCM patients (46% female; mean age 60.6 ± 16.2 years; 74.2% non-Hispanic White; 50% commercial insurance), 89.1% had an ambulatory visit (80.3% office visit, 53.5% OP visits) and 38.0% had a prescription fill. Almost a quarter of patients (23.2%) had an ER visit and 29.6% of patients had an IA over the 5-year follow-up. Cumulative 5-year mean ambulatory visits were 11.2 [13.9] (office visits: 7.3 [9.4], OP visits: 4.0 [8.6]), ER visits 0.5 [1.5], IA 0.7 [2.3], and LOS 7.8 [38.2] days. This translated to a cumulative 5-year total mean CV cost (medical + pharmacy) of $43,533 [$101,631]. Medical costs (total= $43,328 [$101,600]) included total mean ambulatory $9,703 [$25,527] (office visit: $1,447 [$3,752]; OP visit: $8,256 [$24,721]), ER visits $488 [$2,057], IA $27,298 [$88,547], and other medical costs $5,839 [$18,544]. Pharmacy cost over 5-years was $205 [$927]. Conclusions Patients with nHCM experience significant HRU leading to increased costs of care, with almost a quarter of patients having an ER visit and IA. Innovative treatment options to reduce this economic burden and improve patient outcomes are urgently needed for patients with nHCM.